WO2005123772A3 - Anti-cancer therapy - Google Patents

Anti-cancer therapy Download PDF

Info

Publication number
WO2005123772A3
WO2005123772A3 PCT/IL2005/000638 IL2005000638W WO2005123772A3 WO 2005123772 A3 WO2005123772 A3 WO 2005123772A3 IL 2005000638 W IL2005000638 W IL 2005000638W WO 2005123772 A3 WO2005123772 A3 WO 2005123772A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
cancer therapy
nsaid
inflammation
genetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2005/000638
Other languages
French (fr)
Other versions
WO2005123772A2 (en
Inventor
Neriah Yinon Ben
Eli Pikarsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Hadasit Medical Research Services and Development Co
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Medical Research Services and Development Co, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Hadasit Medical Research Services and Development Co
Publication of WO2005123772A2 publication Critical patent/WO2005123772A2/en
Publication of WO2005123772A3 publication Critical patent/WO2005123772A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method of prevention progression from chronic inflammatory condition to cancer, by administration an NF- B inhibitor, anti TNF agent or an NSAID. The method can also be used to prevent cancer in an individual having a high probability (genetic) of developing the types of cancer usually associated with inflammation.
PCT/IL2005/000638 2004-06-17 2005-06-16 Anti-cancer therapy Ceased WO2005123772A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58010604P 2004-06-17 2004-06-17
US60/580,106 2004-06-17

Publications (2)

Publication Number Publication Date
WO2005123772A2 WO2005123772A2 (en) 2005-12-29
WO2005123772A3 true WO2005123772A3 (en) 2006-02-02

Family

ID=35355758

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2005/000638 Ceased WO2005123772A2 (en) 2004-06-17 2005-06-16 Anti-cancer therapy

Country Status (1)

Country Link
WO (1) WO2005123772A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20100266590A1 (en) * 2006-08-02 2010-10-21 Demetri George D Combination therapy
WO2010033315A1 (en) * 2008-09-22 2010-03-25 Amgen Inc. Method of treatment

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BEACHY PHILIP A ET AL: "Mending and malignancy.", NATURE. 23 SEP 2004, vol. 431, no. 7007, 23 September 2004 (2004-09-23), pages 402, XP002356261, ISSN: 1476-4687 *
COUSSENS LISA M ET AL: "Inflammation and cancer.", NATURE (LONDON), vol. 420, no. 6917, 2002, pages 860 - 867, XP002356258, ISSN: 0028-0836 *
LAVON I ET AL: "HIGH SUSCEPTIBILITY TO BACTERIAL INFECTION, BUT NO LIVER DYSFUNCTION, IN MICE COMPROMISED FOR HEPATOCYTE NF-KAPPAB ACTIVATION", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 6, no. 5, May 2000 (2000-05-01), pages 573 - 577, XP000962406, ISSN: 1078-8956 *
LIN ANNING ET AL: "NF-kappaB in cancer: A marked target.", SEMINARS IN CANCER BIOLOGY, vol. 13, no. 2, April 2003 (2003-04-01), pages 107 - 114, XP002356257, ISSN: 1044-579X *
MAYO M W ET AL: "The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance", BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1470, no. 2, 27 March 2000 (2000-03-27), pages M55 - M62, XP004281881, ISSN: 0304-419X *
NICKOLOFF BRIAN J ET AL: "Inflammation and cancer: Is the link as simple as we think?", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 124, no. 6, June 2005 (2005-06-01), pages X - xiv, XP002356260, ISSN: 0022-202X *
PERKINS N D: "The Rel/NF-kappaB family: friend and foe", TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER, HAYWARDS, GB, vol. 25, no. 9, 1 September 2000 (2000-09-01), pages 434 - 440, XP004210315, ISSN: 0968-0004 *
PIKARSKY ELI ET AL: "NF-kappaB functions as a tumour promoter in inflammation-associated cancer", NATURE (LONDON), vol. 431, no. 7007, 23 September 2004 (2004-09-23), pages 461 - 466, XP002356259, ISSN: 0028-0836 *
TOMITA T ET AL: "TRANSCRIPTION FACTOR DECOY FOR NFKB INHIBITS CYTOKINE AND ADHESION MOLECULE EXPRESSIONS IN SYNOVIAL CELLS DERIVED FROM RHEUMATOID ARTHRITIS", RHEUMATOLOGY, OXFORD UNIVERSITY PRESS, LONDON, GB, vol. 39, 2000, pages 749 - 757, XP002951052, ISSN: 1462-0324 *

Also Published As

Publication number Publication date
WO2005123772A2 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
WO2009146111A3 (en) Mobile telephone transaction systems and methods
WO2008066642A3 (en) Transdermal delivery systems comprising bupivacaine
MX2009008794A (en) Pharmaceutical combinations.
WO2005117870A3 (en) Combination of proton pump inhibitor, buffering agent, and prokinetic agent
ATE457708T1 (en) STENT REDUCING SYSTEM
WO2008072093A3 (en) Mobile media platform
EP2030148A4 (en) Systems and methods for implementing parking transactions and other financial transactions
EP1998751A4 (en) Devices, systems and methods for medicament delivery
WO2008019254A3 (en) Reagents, methods and systems to suppress pro-inflammatory cytokines
WO2010060937A3 (en) Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor
WO2008085229A3 (en) Cell-based therapies for treating liver disease
TW200602863A (en) Transaction processing systems and methods utilizing non disk persistent memory
WO2011068927A3 (en) 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
WO2008002678A3 (en) Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use
WO2007143119A3 (en) Method of preventing progression of hypertension-induced heart failure with pkc peptides
GB0701757D0 (en) Systems and methods of conducting financial transactions
WO2006012641A3 (en) Methods for detecting and treating autoimmune disorders
WO2012082821A3 (en) Melanoma treatments
WO2005123772A3 (en) Anti-cancer therapy
WO2009044153A3 (en) Inhibitors and uses
WO2008121899A3 (en) Method of predicting a predisposition to qt prolongation
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
MX2009004143A (en) Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome.
WO2008058033A3 (en) Soluble epoxide hydrolase inhibitors for the treatment of rheumatoid arthritis
WO2005076888A3 (en) Anti-cancer therapies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase